No 'Wearing-off Effect' Seen in Quarterly or Monthly Dosing of Fremanezumab: Sub-analysis of a Randomized Long-term Study.

CONCLUSIONS: This analysis of data from a long-term, phase 3 study showed that patients receiving quarterly fremanezumab or monthly fremanezumab did not experience a wearing-off effect towards the end of the dosing interval. PMID: 33009665 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33009665?dopt=Abstract

Source: Headache - October 1, 2020 Category: Neurology Authors: Blumenfeld AM, Stevanovic DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B, Tepper SJ Tags: Headache Source Type: research

More News: Disability | Headache | Migraine | Neurology | Study